Founder & CEO of Revolution Biomanufacturing Inc. (RBIx), building a category-defining platform company transforming how personalized mRNA therapeutics are developed and manufactured. Creating a scalable, capital efficient model to deliver precision medicines faster, reduce development risk, and unlock new markets in individualized care. • Driving end-to-end platform strategy integrating AI enabled sequence design with agile, modular manufacturing to compress timelines and increase probability of technical success for personalized medicine. • Secured exclusive global rights to five patent families from Kudo Biotechnology, establishing a defensible IP position and multiple monetization pathways through partnerships and sublicensing. • Architecting a high-growth business model targeting recurring revenue streams across development services, manufacturing, and platform-enabled therapeutics. • Positioning RBIx to address large and expanding markets in oncology, rare disease, and rapid-response therapeutics, where speed and customization are critical value drivers. • Building strategic partnerships to accelerate market entry, de-risk scale-up, and expand technical capabilities without heavy fixed infrastructure early. • Actively raising capital to build a first-in-class, flexible GMP manufacturing platform designed for personalized medicine, enabling high margin, low volume, high value production. • Focused on disciplined execution, capital efficiency, and creating a platform capable of both service revenue and long term asset value through pipeline and IP expansion. • Secured five client projects within the first year of operations, demonstrating rapid market traction and commercial execution.

Reporting to the Board of Directors, the primary responsibility is to lead the Company, including ownership of business plans, operations, strategy, finances, team growth, people management, SOPs, performance metrics, cross-functional collaboration, commercial and corporate growth, global regulatory compliance, and innovation development. • Responsible for building the Company from start-up to develop oversight and vision in establishing the mRNA CDMO business, strategic, operational, and growth plans to a $150M per annum business by 2025. • Establish and execute both short and long-range business goals, strategies, plans, policies, and mission/core values designed to accommodate the growth objectives and vision. • Build scalable operations and the methods and metrics to plan, forecast, and track them. • Lead and maintain oversight of daily operations. Development and implementation of company-wide systems, processes, SOPs, project management tools, regulatory compliance, GMP, and management of budget and forecasting reviews to achieve the overall financial goals. • Build relationships and successfully collaborate with internal cross-functional teams/stakeholders/leaders, and complementary external vendors and customer base. • Won the Advanced Therapies Award's "Women in Advanced Therapies Award 2025," which recognizes individuals who have made significant contributions to the field of advanced therapies. This award aims to honor those who have advanced knowledge and skills in the treatment of advanced therapies, particularly in areas such as treatment-resistant prostate cancer and other innovative therapeutic approaches.

Consulting for multiple CDMOs in the Biologics Large Molecule space. Guiding Senior leadership to develop and manage a market assessment, key strategic targeting, operational design for new market entrance, business performance program to measure key performance indicators, identifying trends, and utilizing insights to help drive growth, earnings, and cost improvement. • Led the development and management of a strategic framework for business core competencies programs to drive growth and improve business performance. • Collaborate with Senior leaders, including sales, marketing, process science, engineering, manufacturing, network management, and operations, to identify and operationalize key performance indicators and outcome measures in their respective functional areas. • Guide steering committees, coordinate cross-functional workgroups, and work with leadership in support of business performance initiatives for entry into new modalities and markets. • Developed content and business cases for key initiatives in support of the business performance programs and strategic business plans. • Chief Strategy Officer on a fractional basis. Led fund-raising Series B for a List Bio a startup Microbiome CDMO in the USA. This role involved establishing Strategic Business, Strategic Marketing, and “Go to Market” Service offering plans, creating a CDMO process, laying out a roadmap to positive revenue, and assessing technical competence and intellectual property. Most importantly, managing the day-to-day of fundraising.

Led day-to-day operations for a $50M USD Contract Manufacturing Organization specializing in Gene and Cell Therapy. Led a 130-person company in functional areas of research, quality control, process science, and manufacturing of both viral vectors and pDNA. Full Profit and Loss responsibility reporting to the Board of Directors. Tasked with commissioning two new commercial 60,000 Sq Ft sites with both Microbial fermentation (DNA Plasmids) and Mammalian cell culture (Viral Vectors) capability, while qualifying the existing facility for European and US FDA requirements. Led all due diligence activities in the sale of the company. Increased shareholder equity by 92% leading up to the acquisition by Charles River Laboratories for $350M USD in June 2021.

Built and launched a global biologics CDMO by consolidating and transforming the assets of three failed startups into a unified, commercially viable platform. Defined and executed the full go-to-market strategy, converting underutilized infrastructure into a revenue-generating organization with a clear competitive position. Established integrated end-to-end capabilities spanning mammalian and microbial drug substance through sterile fill/finish and lyophilization, creating a scalable offering positioned for rapid client acquisition and long-term growth. • Built the Company from inception into a fully integrated operational/commercial organization. • Charged with the in-licensing of the appropriate technology to support the venture in cell line and scientific first-in-class manufacturing technology. • Recruited and reorganized an executive management team and decision-making process to include the deal to delivery. • Managed M&A deals of two facilities. • Developed and implemented internal performance management and Key Performance Indicator systems. • Responsible for full P&L and global management of the CDMO organization. • Led a cross-functional team with over 350+ reports.

Built and scaled a new biologics CDMO business unit within BioVectra, establishing a fully integrated platform from concept to commercial readiness. Led the end-to-end strategy, including facility design, market entry, and long-range growth planning, while defining differentiated service offerings and securing enabling technologies. Architected the commercial and operational blueprint for launch, including biosimilar and regenerative medicine strategy, go-to-market execution, and strategic partnerships positioning the business unit for rapid revenue generation, competitive market entry, and long-term enterprise value creation. • Directed all business functions to include drug development, commercial planning, strategic partnering and alliances, licensing, business development activities, and transactions. • Full P&L responsibilities for the Biologic CDMO business unit. Identified, cultivated relationships, closed deals, and implemented strategic alliances and collaborations. • Closed over $350M USD in clinical and commercial contracts within the timeframe.